“Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s12. doi:10.25251/skin.1.supp.11.